WALTHAM, Mass., Nov. 17, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel biomarker-based diagnostics, announced today that results from a study on the role of galectin-3 in patients with end-stage renal disease (ESRD) were presented at the American Heart Association’s Scientific Sessions 2011 (AHA) meeting in Orlando, Florida on November 16, 2011. Results from this study suggest that galectin-3 may be an independent predictor of adverse outcomes in patients with ESRD, due to the association of galectin-3 with all-cause and infectious mortality, stroke and other cardiovascular events. The data were featured in a presentation entitled, “Galectin-3 and Outcomes in Patients with End-Stage Renal Disease: Data from the German Diabetes and Dialysis Study,” presented by Rudolf de Boer, MD, PhD, Associate Professor of Cardiology at the University of Groningen, the Netherlands. In the study, patients’ galectin-3 levels were measured using the BGM Galectin-3TM test.
